Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Paganini Biopharma

2013 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of therapeutics for cancer treatment. The company's therapeutics for cancer treatment include development of anti-epithelial membrane protein 2 (EMP2) fully human monoclonal antibody, ONCR-201 to treat tumors, enabling patients to get treated against breast cancer including triple negative, ovarian cancer and endometrial cancer.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Acquirer
Primary Office
  • 17328 Ventura Boulevard
  • Suite 147
  • Encino, CA 91316
  • United States

Paganini Biopharma Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Paganini Biopharma‘s full profile, request access.

Request full access to PitchBook

Paganini Biopharma Executive Team (4)

Name Title Board
Seat
Contact
Info
Gary Lazar MD President & Chief Executive Officer
Jonathan Braun Co-Founder
Lynn Gordon Co-Founder
Madhuri Wadehra Ph.D Co-Founder